Ethinylestradioldienogest in oral contraception

Drugs

Volumn 70, Issue 6, 2010, Pages 681-689

  Prez Campos, Ezequiel F ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; APOLIPOPROTEIN A1; DIENOGEST; DIENOGEST PLUS ETHINYLESTRADIOL; ETHINYLESTRADIOL; GESTODENE; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEVONORGESTREL; LIOTHYRONINE; ORAL CONTRACEPTIVE AGENT; SOMATOMEDIN C; THYROXINE; DRUG DERIVATIVE; NANDROLONE;

ACNE VULGARIS; ANDROGEN BLOOD LEVEL; BLOOD PRESSURE; BLOOD SAMPLING; BREAST TENDERNESS; BREAST TENSION; CARBOHYDRATE METABOLISM; CLINICAL TRIAL; DEPRESSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DYSMENORRHEA; EDEMA; FERTILITY; GASTROINTESTINAL SYMPTOM; GERMANY; GROWTH HORMONE BLOOD LEVEL; HAIR; HEADACHE; HUMAN; LIBIDO; LIOTHYRONINE BLOOD LEVEL; LIPID METABOLISM; LIVER FUNCTION; LOW DRUG DOSE; LUNG EMBOLISM; MASTALGIA; MAXIMUM PLASMA CONCENTRATION; MENSTRUAL CYCLE; MENSTRUATION; METAPLASIA; MIGRAINE; NAUSEA; ORAL CONTRACEPTION; PAIN; PHARMACODYNAMICS; PHLEBITIS; PROTEIN BLOOD LEVEL; REVIEW; SIDE EFFECT; SKIN; THROMBOPHLEBITIS; THROMBOSIS; THYROID HORMONE BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREATMENT DURATION; UTERUS PAIN; VENOUS THROMBOEMBOLISM; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; FEMALE; METABOLISM;

ANIMALS; CONTRACEPTIVES, ORAL, COMBINED; ETHINYL ESTRADIOL; FEMALE; HUMANS; MENSTRUAL CYCLE; NANDROLONE;

EID: 77951083053     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11536320-000000000-00000     Document Type: Review

References (42)

1. Moore C, Feichtinger W, Klinger G, et al. Clinical findings with the dienogest-containing oral contraceptive Valette. Drugs Today 1999; 35 Suppl. C: 53-68 (Pubitemid 29342747)
2. Zimmermann T, Dietrich H, Wisser K-H, et al. The efficacy and tolerability of Valette: a postmarketing surveillance study. Eur J Contracept Reprod Health Care 1999; 4: 155-164
3. Wiegratz I, Mittmann K, Dietrich H, et al. Fertility after discontinuation of treatment with an oral contraceptive containing 30 microg of ethinyl estradiol and 2 mg of die-nogest. Fertil Steril 2006 Jun; 85 (6): 1812-1819
4. Sabra A, Bonnar J. Hemostatic system changes induced by 50 micrograms and 30 micrograms estrogen/progestogen oral contraceptives: modification of estrogen effects by le-vonorgestrel. J Reprod Med 1983 Jan; 28 (1 Suppl.): 85-91
5. Bonnar J. Coagulation effects of oral contraception. Am J Obstet Gynecol 1987 Oct; 157 (4 Pt 2): 1042-1048
6. Bonnar J, Daly L, Carroll E. Blood coagulation with a combination pill containing gestodene and ethinyl estra-diol. Int J Fertil 1987; 32 Suppl.: 21-28
7. Wiegratz I, Lee JH, Kutschera E, et al. Effect of dienogestcontaining oral contraceptives on lipid metabolism. Contraception 2002 Mar; 65 (3): 223-229
8. Zimmermann H, Duvauchell T, Gualano V, et al. Pharmacokinetics of dienogest as a single drug or in combination with estradiol valerate or ethinylestradiol. Drugs Today 1999; 35 Suppl. C: 27-39
9. Kuhl H. Dienogest: a viewpoint by Herbert Kuhl. Drugs 1998; 56 (5): 834
10. Foster RH, Wilde MI. Dienogest. Drugs 1998; 56 (5): 825-33
11. Oettel M, Carol W, Elger W, et al. A 19-norprogestin without a 17alpha-ethinyl group. II: dienogest from a phar-macodynamic point of view. Drugs Today 1995; 31: 517-536 (Pubitemid 26031142)
12. Golbs S, Domhardt R, Presl J, et al. Clinical findings with the oral contraceptive combination ethinylestradiol/dieno-gest in the Czech Republic. Methods Find Exp Clin Pharmacol 2002 Dec; 24 (10): 689-696 (Pubitemid 36188278)
13. Golbs S, Domhardt R, Radowicky S, et al. Clinical findings with the oral contraceptive combination ethinylestra-diol/dienogest in Poland. Methods Find Exp Clin Pharmacol 2002 Nov; 24 (9): 585-592 (Pubitemid 36109398)
14. Goldzieher JW. Pharmacokinetics and metabolism of ethinyl estrogens. In: Goldzieher JW, Fotherby K, editors. Pharmacology of the contraceptive steroids. New York: Raven Press Ltd, 1994: 127-152
15. Goldzieher JW, Stanczyk FZ. Oral contraceptives and individual variability of circulating levels of ethinyl estradiol and progestins. Contraception 2008 Jul; 78 (1): 4-9
16. Oettel M, Bervoas-Martin S, Elger W, et al. A 19-norprogestin without a 17alpha-ethinyl group. I: dienogest from a pharmacokinetic point of view. Drugs Today 1995; 31: 499-516 (Pubitemid 26031141)
17. Sanger N, Stahlberg S, Manthey T, et al. Effects of an oral contraceptive containing 30mcg ethinyl estradiol and 2mg dienogest on thyroid hormones and androgen parameters: conventional vs. extended-cycle use. Contraception 2008 Jun; 77 (6): 420-425
18. Moore C, Luderschmidt C, Moltz L, et al. Antiandrogenic properties of the dienogest-containing oral contraceptive Valette. Drugs Today 1999; 35 Suppl. C: 69-78 (Pubitemid 29342748)
19. Wiegratz I, Kutschera E, Lee JH, et al. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception 2003 Jan; 67 (1): 25-32
20. Kohler G, Goretzlehner G, Brachmann K. Lipid metabolism during treatment of endometriosis with the progestin dienogest. Acta Obstet Gynecol Scand 1989; 68 (7): 633-635 (Pubitemid 20145523)
21. Spona J, Feichtinger W, Kindermann C, et al. Double-blind, randomized, placebo controlled study on the effects of the monophasic oral contraceptive containing 30 micrograms ethinyl estradiol and 2.00mg dienogest on the hemostatic system. Contraception 1997 Aug; 56 (2): 67-75
22. Wiegratz I, Stahlberg S, Manthey T, et al. Effects of conventional or extended-cycle regimen of an oral contraceptive containing 30mcg ethinylestradiol and 2 mg dienogest on various hemostasis parameters. Contraception 2008 Nov; 78 (5): 384-391
23. Balogh A, Kauf E, Vollanth R, et al. Effects of two oral contraceptives on plasma levels of insulin-like growth factor I (IGF-I) and growth hormone (hGH). Contraception 2000 Nov; 62 (5): 259-269
24. Wiegratz I, Kutschera E, Lee JH, et al. Effect of four oral contraceptives on thyroid hormones, adrenal and blood pressure parameters. Contraception 2003 May; 67 (5): 361-366
25. Scheussner E, Michels W, Bethge S, et al. Die Wirkung von Dienogest auf die hypothalamisch-hypophysare Achse: Ergebnisse einer Pilotstudie. In: Teichmann AT, editor. Dienogest-Ptaklinik unf Klinik eines neuen Gestagens. Berlin: Walter de Gruyter, 1995: 171-179
26. Carol W, Jager R, Martin P, et al. The behavior of cytoplasmic progesterone receptors in the cycling endometrium and the effect of hormonal contraceptives. Zentralbl Gy-nakol 1989; 111 (12): 793-799
27. Fu L, Osuga Y, Morimoto C, et al. Dienogest inhibits BrdU uptake with G0/G1 arrest in cultured endometriotic stro-mal cells. Fertil Steril 2008 May; 89 (5 Suppl.): 1344-1347
28. Graser T, Oettel M. Organ targeting with the oral progestin dienogest. Drugs Today 1996; 32 Suppl. H: 43-55
29. Okada H, Nakajima T, Yoshimura T, et al. The inhibitory effect of dienogest, a synthetic steroid, on the growth of human endometrial stromal cells in vitro. Mol Hum Re-prod 2001 Apr; 7 (4): 341-347
30. Spona J, Feichtinger W, Kindermann C, et al. Modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00mg dienogest. Contraception 1997 Sep; 56 (3): 185-191
31. Elstein M, Furniss H. The fiction of an ideal hormonal contraceptive. Adv Contracept 1996 Jun; 12 (2): 129-138
32. Brill K. Minimizing the problem of poor compliance in adolescents: clinical experience with a modern low-dose gestodene-containing oral contraceptive. Ann N Y Acad Sci 1997 Jun 17; 816: 457-465
33. Brill K, Norpoth T, Schnitker J, et al. Clinical experience with a modern low-dose oral contraceptive in almost 100,000 users. Contraception 1991; 43: 101-110
34. Fotherby K. Twelve years of clinical experience with an oral contraceptive containing 30 micrograms ethinyloestradiol and 150 micrograms desogestrel. Contraception 1995 Jan; 51 (1): 3-12
35. Archer DF, Maheux R, DelConte A, et al. A new lowdose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 micrograms and ethinyl estradiol 20 micrograms: North American Levonorgestrel Study Group (NALSG). Contraception 1997 Mar; 55 (3): 139-144
36. Zimmermann T, Dietrich H, Wisser KH, et al. Fertility after discontinuation of the dienogest-containing oral contraceptive Valette: first data of an ongoing study. Drugs Today 1999; 35 Suppl. C: 89-95
37. Dunson DB, Baird DD, Colombo B. Increased infertility with age in men and women. Obstet Gynecol 2004 Jan; 103 (1): 51-56
38. Palombo-Kinne E, Schellschmidt I, Schumacher U, et al. Efficacy of a combined oral contraceptive containing 0.030mg ethinylestradiol/2mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035mg ethinylestradiol/2 mg cyproterone acetate. Contraception 2009 Apr; 79 (4): 282-289
39. Zimmermann T, Wisser KH, Dietrich H. Effects of the dienogest-containing oral contraceptive Valette on skin and hair: results of a postmarketing surveillance study. Drugs Today 1999; 35 Suppl. C: 97-104 (Pubitemid 29342751)
40. Zimmermann T, Wisser KH, Dietrich H. The effects of Valette on skin and hair: a post-marketing surveillance study. Int J Clin Pract 2000 Mar; 54 (2): 85-91
41. Zimmermann T, Dietrich H, Wisser KH, et al. Efficacy and tolerability of the dienogest-containing oral contraceptive Valette: results of a postmarketing surveillance study. Drugs Today 1999; 35 Suppl. C: 79-87 (Pubitemid 29342749)
42. Jick SS, Kaye JA, Russmann S, et al. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel. Contraception 2006 Jun; 73 (6): 566-570